Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
- Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
- 02/26/2025
|
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.
- 02/26/2025
|
Alector to Participate in Upcoming Healthcare Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
- 02/25/2025
|
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
- SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.
- 02/19/2025
|
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
- Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration
- 01/13/2025
|
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
- Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
- 12/04/2024
|
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
- Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
- 11/27/2024
|
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
- On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
- 11/26/2024
|
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
- SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.
- 11/25/2024
|
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
- SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.
- 11/14/2024
|
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
- Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
- 11/06/2024
|
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
- Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
- 11/06/2024
|
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
- OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
- 10/23/2024
|
Alector to Participate in Upcoming Healthcare Conferences
- SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
- 08/29/2024
|
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
- Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.
- 08/08/2024
|
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
- Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
- 08/07/2024
|
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
- Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024
- 08/07/2024
|
Alector to Host Mid-Year Earnings Conference Call
- Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
- 07/31/2024
|
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
- --INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--
- 07/28/2024
|
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
- SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024.
- 07/23/2024
|
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
- Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
- 06/10/2024
|
Alector to Participate in Upcoming Healthcare Conferences
- SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
- 05/09/2024
|
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
- Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.
- 05/08/2024
|
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
- Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2024
|
Alector to Participate in Upcoming Healthcare Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
- 02/28/2024
|
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
- Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
- 02/27/2024
|
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023
- 02/27/2024
|
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
- Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
- 02/20/2024
|
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
- Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/20/2024
|
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
- Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/08/2024
|
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease
- The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
- 02/08/2024
|
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
- -Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of FTD-GRN-
- 02/07/2024
|
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
- Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/25/2024
|
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
- Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
- 01/23/2024
|
Alector Announces Closing of Public Offering
- SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its common stock in the offering. Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock. The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.
- 01/19/2024
|
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
- Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.
- 01/17/2024
|
Alector Announces Pricing of Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. All of the shares in the offering are being sold by Alector.
- 01/17/2024
|
Alector Announces Proposed Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares in the proposed offering are being sold by Alector.
- 01/16/2024
|
Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/05/2023
|
These biotechs targeting multiple neurodegenerative diseases
- Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.
- 12/01/2023
|
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
- Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively
- 11/28/2023
|
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 11/14/2023
|
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
- Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
- 09/08/2023
|
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/10/2023
|
Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates
- Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.
- 08/03/2023
|
Alector to Host Mid-Year Earnings Conference Call
- Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT
- 07/27/2023
|
7 Stocks That AI Says Will Make You a Millionaire by 2025
- Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, how can you benefit from this powerful technology?
- 07/13/2023
|
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 10:40 a.m. PT.
- 06/06/2023
|
Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?
- The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 05/09/2023
|
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
- Alector (ALEC) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.54 per share a year ago.
- 05/04/2023
|
Alector: Trading At Cash Despite Late Stage CNS Pipeline
- Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals.
- 02/03/2023
|
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
- Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study.
- 10/04/2022
|
Alector: Potential In Neurology And Cancer Treatments
- Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Disease and Parkinson's Disease.
- 06/14/2022
|
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 2:00 p.m. PT.
- 06/08/2022
|
New Strong Sell Stocks for May 2nd
- ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
- 05/02/2022
|
Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?
- Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/01/2022
|
Alector, Inc: A Newer Biotech Company With Big Potential
- Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector has benefited from the same positive trend in financials despite being one of the few companies not targeting COVID-19 treatments.
- 01/26/2022
|
Alector, Inc: A stock with its eyes on the future
- Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.
- 12/18/2021
|
Alector (ALEC) Lags Q3 Earnings and Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
- Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET
- 11/03/2021
|
Alector: The GSK Deal Is A Major Value Add
- Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK.
- 10/29/2021
|
Alector Announces Appointment of Elizabeth A. Garofalo, M.D.
- SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology.
- 09/28/2021
|
Why Alector Shares Are Diving Today
- There has been a major shakeup in the C-suite.
- 09/08/2021
|
Alector Provides Executive Leadership Update
- Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer
- 09/07/2021
|
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2021
|
Alector Reports Second Quarter 2021 Financial Results
- Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)
- 08/03/2021
|
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
- Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2021
|
Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
- Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotemporal dementia decline because they're missing one copy of an immune-regulating gene called progranulin and subsequently have half the amount of the protein healthy adults have.
- 07/29/2021
|
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation
- AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients
- 07/29/2021
|
Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Association International Conference
- Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET
- 07/21/2021
|
Alector's (ALEC) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).
- 07/12/2021
|
Why Alector Zoomed 12% Higher Today
- The company has yet another fine July trading day thanks to a Citigroup analyst.
- 07/06/2021
|
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
- Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
- 07/05/2021
|
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
- Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.
- 07/05/2021
|
Alector (ALEC) Stock Jumps 57.1%: Will It Continue to Soar?
- Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 07/05/2021
|
Why Alector Blasted Higher Today
- It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.
- 07/02/2021
|
Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring
- One of these companies is making big waves.
- 07/02/2021
|
ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher
- Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher appeared first on InvestorPlace.
- 07/02/2021
|
Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK
- Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin (PGRN) levels. PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders.
- 07/02/2021
|
Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
- SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments.
- 07/02/2021
|
Alector to Present at Upcoming Virtual Healthcare Conferences
- SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:
- 06/03/2021
|
Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
- SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) on Friday, June 11, 2021 at 10:30 a.m. ET.
- 05/26/2021
|
Alector: Pioneering Approach In CNS Diseases
- Alector is doing pioneering work in various neurodegenerative diseases including Alzheimer's.
- 05/18/2021
|
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
- Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2021
|
Alector Reports 2021 First Quarter Financial Results and Provides Business Update
- SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and financial results for the first quarter ended March 31, 2021.
- 05/05/2021
|
Alector to Present at Stifel's 3rd Annual CNS Day
- SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at Stifel's 3rd Annual CNS Day on Thursday, April 1, 2021, at 9:30 a.m. ET.
- 03/25/2021
|
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
- Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis announced positive results for the Phase 3 study of Rubraca in ovarian cancer.
- 03/19/2021
|
Alector to Present at the Barclays Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 2:25 p.m. ET.
- 03/04/2021
|
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's Disease
- SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer's disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia, which serve as the immune cells in the brain. The AL002 clinical program is being developed in collaboration with AbbVie.
- 01/25/2021
|
Alector Announces Departure of Chief Business Officer
- SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be leaving the Company to pursue other opportunities. Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer, will serve as interim CBO, overseeing the business development, finance, communications, facilities, and IT departments. The transition will be effective as of February 1, 2021 and Dr. Oney will remain as an employee and advisor to Alector until May 3, 2021.
- 01/20/2021
|
Alector Provides 2021 Corporate Portfolio Update
- SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned clinical and research priorities for 2021.
- 01/07/2021
|
Alector: Activating Microglia To Treat Neurodegeneration
- Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.
- 12/28/2020
|
Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside
- Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzheimer's and Frontotemporal Dementia. Alector also has 2-preclinical therapeutics, and 8 in the research phase.
- 12/07/2020
|
Alector to Present at the Stifel 2020 Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 4:40 p.m. ET.
- 11/11/2020
|
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2020
|
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the third quarter ended September 30, 2020.
- 11/10/2020
|
Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbitrator issued an interim, confidential decision in favor of the company in its dispute with Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Prevail Therapeutics. The arbitrator found Dr. Abeliovich liable for breach of his consulting agreement with Alector and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement, and sanctions for the spoliation as well as violation of orders during the proceeding. The monetary amounts of the damages and sanctions will be determined in further proceedings.
- 11/02/2020
|
Alector (ALEC) Investor Presentation - Slideshow
- The following slide deck was published by Alector, Inc. in conjunction with this event..
- 09/14/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/13/2020
|
Stocks To Watch: Apple, Snowflake, Pfizer And Moderna In Focus
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/12/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Alector (ALEC) Reports Q2 Loss, Misses Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2020
|
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- * Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) * Promising preliminary data from AL001 Phase 1b and Phase 2 open-label studies presented at Alzheimer’s Association International Conference * AL002, AL003 and AL014 programs for the treatment of Alzheimer’s disease and AL101 neurology program continue to progress * Strong cash and investments of $503.6 million to support execution of clinical, research and operational goalsSOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the second quarter ended June 30, 2020.“I am proud of the continued progress across our portfolio, most notably the initiation of our pivotal Phase 3 trial evaluating AL001 for the treatment of people with frontotemporal dementia,” said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. “We are encouraged by the findings from the Phase 2 study of AL001 and look forward to sharing additional data after longer-term treatment and follow up. Our novel immuno-neurology approach and commitment to delivering transformative new therapies to people living with devastating forms of degenerative brain diseases are at the core of what we do. We have taken significant steps to ensure that we will continue to be in a position to achieve our goals, and ultimately, deliver therapies to the people who need them.”Clinical Pipeline Highlights and Corporate UpdateProgranulin Portfolio: * Announced dosing of first participant in pivotal Phase 3 trial evaluating AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In July 2020, Alector announced that the first participant was dosed in INFRONT-3, a global, pivotal Phase 3 trial, evaluating the efficacy and safety of AL001 in pre-symptomatic and symptomatic participants with FTD-GRN. The trial will enroll up to 180 participants at approximately 50 centers globally. * Presented preliminary findings from AL001 Phase 1b and Phase 2 open label studies at the Alzheimer’s Association International Conference (AAIC). In July 2020, Alector presented promising preliminary data from the Phase 1b and Phase 2 open-label studies evaluating the long-term dosing of AL001 in patients with FTD-GRN at the virtual AAIC. The data demonstrated that AL001 was well-tolerated in both studies. Additionally, in the Phase 2 study, treatment with AL001 led to sustained restoration of plasma progranulin (PGRN) levels in all FTD-GRN participants back to the normal range. These preliminary findings also showed that the majority of symptomatic FTD-GRN participants (six out of the eight) experienced a decrease in neurofilament light chain levels (NfL), an exploratory biomarker of neurodegeneration, from baseline at the last measured time point. Alector plans to continue this 96-week open-label Phase 2 study and present additional data from study participants, including findings on safety, fluid and imaging biomarkers, and clinical outcomes assessments, at a later date.Alzheimer’s Disease Portfolio: * Continued progress for multiple Alzheimer’s disease clinical programs: * In collaboration with its partner AbbVie, Alector plans to initiate a Phase 2 study evaluating AL002 in patients with Alzheimer’s disease in the second half of 2020. * Alector continues to advance the Phase 1b trial of AL003 in Alzheimer’s disease, also being developed in collaboration with AbbVie. * Alector plans to initiate Phase 1 development for AL014 in the first half of 2021. AL014 is the latest prioritized candidate that targets MS4A4A, a transmembrane receptor protein that is expressed selectively in microglia in the brain and is associated with control of microglia functionality and potential viability.Notable Clinical and Early-Stage Research: * Published new findings from the AL002 program in leading research journal. In June 2020, Alector announced the publication of preclinical and Phase 1 data demonstrating the potential of AL002 as a treatment for Alzheimer’s disease in The Journal of Experimental Medicine. * Published research showing role of Trem2 in a multiple sclerosis disease model. In August 2020, Alector researchers and academic collaborators published findings highlighting the role of Trem2 as induced by AL002a (a murine specific Trem2 antibody) in promoting myelin debris clearance and remyelination in a cuprizone mouse model of multiple sclerosis in Acta Neuropathologica.Ongoing COVID-19 Response Activities: * Alector continues to actively monitor the evolving impact of COVID-19 on its business and clinical operations, with a primary focus on the health and safety of clinical trial participants, clinical trial site teams and employees. * To help mitigate the potential effects of the ongoing COVID-19 pandemic on current participant recruitment activities, the Company has implemented a number of activities to enhance clinical trial continuation and patient recruitment including: increased remote support for clinical sites and study staff; evaluation of the availability of in-home dosing and monitoring services for trial participants; and concierge travel support for trial participants who prefer to visit clinical sites in person. A targeted disease education campaign is also planned to help drive awareness of FTD and the AL001 Phase 3 clinical trial.Second Quarter 2020 Financial ResultsRevenue. Collaboration revenue for the quarter ended June 30, 2020, was $3.2 million, compared to $6.9 million for the same period in 2019. Alector recognizes revenue from the upfront payments under an agreement with AbbVie over time as the services are provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Changes in estimates for revenue recognized over time are recognized on a cumulative basis.R&D Expenses. Total research and development expenses for the quarter ended June 30, 2020, were $34.1 million, compared to $25.6 million for the same period in 2019. This increase was mainly driven by an increase in expenses to support the advancement of the clinical and pre-clinical programs across several therapeutic programs and an increase in personnel-related expenses.G&A Expenses. Total general and administrative expenses for the quarter ended June 30, 2020, were $15.7 million, compared to $8.4 million for the same period in 2019. This increase was primarily due to an increase in personnel-related expenses due to increased headcount and an increase in legal costs associated with our ongoing arbitration proceedings for certain intellectual property matters.Net Loss. For the quarter ended June 30, 2020, Alector reported a net loss of $45.3 million, compared to a net loss of $24.6 million for the same period in 2019.Cash Position. Cash, cash equivalents, and marketable securities were $503.6 million as of June 30, 2020. The Company believes that its cash and investments as of June 30, 2020, will be sufficient to fund its anticipated operations through 2022.About Alector Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions, Alector and its business as set forth in Alector’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2020, as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
- 08/11/2020
|
SG Americas Securities LLC Has $334,000 Stock Holdings in Alector Inc (NASDAQ:ALEC)
- SG Americas Securities LLC grew its stake in Alector Inc (NASDAQ:ALEC) by 35.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,648 shares of the company’s stock after acquiring an additional 3,608 shares during the period. SG Americas Securities LLC’s holdings […]
- 08/11/2020
|
Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript
- Orchard Therapeutics plc (NASDAQ:ORTX) Q2 2020 Results Conference Call August 06, 2020 08:00 AM ET Company Participants Renee Leck - Investor Relations Bobby Gaspar - Chief Executive Officer Frank Thomas - Chief Operating Officer Conference Call Participants Yaron Werber - Cowen Anupam Rama - JP Morgan Peter Kim - Barclays David Nierengarten - Wedbush Securities Anna Vorobyeva-Schiano - Goldman Sachs Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.
- 08/08/2020
|
Alector Looks Like A Buy After Huge Selloff (NASDAQ:ALEC)
- Alector released preliminary data from its ongoing Phase 2 trial of AL001 in frontotemporal dementia on July 28.
- 08/07/2020
|
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
- SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.About Alector Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.Contacts Media Erica Jefferson Vice President, Communications and Public Affairs Alector, Inc. 301-928-4650 erica.jefferson@alector.com1AB Dan Budwick 973-271-6085 dan@1abmedia.comorInvestors: Alector, Inc. ir@alector.com
- 08/04/2020
|
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
- Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Why Alector Is Tumbling 28.7% Today
- Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.
- 07/29/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Fulgent Genetics Inc (NASDAQ: FLGT) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * Medpace Holdings Inc (NASDAQ: MEDP) (saw an extension of its earnings-induced momentum) * NeoGenomics, Inc. (NASDAQ: NEO)(reacted to its second-quarter results) * OncoSec Medical Inc (NASDAQ: ONCS) * Penumbra Inc (NYSE: PEN) * Qiagen NV (NYSE: QGEN) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Trevena Inc (NASDAQ: TRVN) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) * Nkarta Inc (NASDAQ: NKTX) * Nurix Therapeutics Inc (NASDAQ: NRIX)(IPOed Friday) * Verrica Pharmaceuticals Inc (NASDAQ: VRCA) * Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)Stocks In Focus Alector Slips After Presenting Dementia Drug Trial Results Alector Inc (NASDAQ: ALEC) announced at the virtual 2020 Alzheimer's Association International Conference, or AAIC, preliminary results from a Phase 1b and open-label Phase 2 studies of AL001 for the treatment of people with frontotemporal dementia with a progranulin gene mutation, or FTD-GRN, with the Phase 1 study showing AL001 was generally safe and well-tolerated.The company also said the Phase 2 study showed that treatment with AL001 resulted in sustained restoration of plasma progranulin levels in all FTD-GRN participants back to normal range and the majority of symptomatic FTD-GRN participants showed a decrease in plasma neurofilament light chain levels from baseline.The stock fell 10.97% to $19 in after-hours trading.Sonoma's Sanitizer Meets Standards For Use In Aircraft Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) and its distribution partner MicroSafe Group Dubai announced that Microsafe Disinfectant & Sanitizer manufactured by Sonoma successfully passed both the Boeing Co (NYSE: BA) Specification Standard BSS7434 and the British Aerospace Airbus SE (OTC: EADSY) specification AIMS09-00-002.The passing of these tests validate the compatibility and safety of the product on the interior and exterior parts and materials of Boeing and Airbus commercial transport aircraft, Sonoma said.Sonoma shares jumped 70.28% to $11 in after-hours trading.Sanofi-Glaxo Agrees to Supply U.K. 60M Doses of Coronavirus Vaccine Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) said they have reached an agreement, subject to final contract, with the U.K. government for the supply of up to 60 million doses of a COVID-19 vaccine.The companies expect a Phase 1/2 study to start in September, followed by a Phase 3 study by the end of 2020. The companies are also in talk with the European Commission, France and Italy and also other governments to ensure global access to the vaccine.Separately, Sanofi reported a 4.9% drop in first-half sales but business EPS grew 9.2%. The company raised its full-year EPS growth forecast.Merck's Oncology Drug Gets Breakthrough Designation Merck & Co., Inc. (NYSE: MRK) said the FDA has granted Breakthrough Therapy designation to the hypoxia-inducible factor-2 alpha inhibitor MK-6482, a novel investigational candidate in its oncology pipeline, for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma. The FDA also granted orphan drug designation to MK-6482 for VHL disease.Roche's COVID-19 Treatment Candidate Flunks a Late-stage Study Roche Holdings AG's (OTC: RHHBY) Genetech unit said a Phase III COVACTA study of Actemra did not meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. Key secondary endpoints, which included the difference in patient mortality at week four, were not met, the company said.Pacira Reaches $3.5M Settlement Agreements With Respect to Its Non-opioid Pain Drug Pacira Biosciences Inc (NASDAQ: PCRX) announced settlement agreements that resolve all outstanding investigations and claims by the U.S. Department of Justice, the U.S. Department of Health and Human Services, various States Attorneys' General, and a private plaintiff. The company, however, said, it expressly denies all allegations and contentions and has admitted no wrongdoing in connection with the settlement agreements.The five-year investigation related to the sale and marketing of Exparel, Pacira's long-acting non-opioid local analgesic for postsurgical pain management. Under the various settlement agreements, Pacira will pay about $3.5 million.Earnings Masimo Corporation (NASDAQ: MASI) reported second-quarter revenues rose 31% to $301 million and non-GAAP net income climbed from 76 cents to 85 cents, while analysts estimated EPS of 81 cents. The company did not give guidance, citing COVID-19 uncertainties.View more earnings on IBBThe stock moved down 3.12% to $228 in after-hours trading.AtriCure Inc.'s (NASDAQ: ATRC) second-quarter revenues fell 30.7% to $40.8 million, and net loss per share widened from 11 cents to 20 cents. Analysts estimated a loss of 57 cents per share.In after-hours trading, the stock was down 3.09% to $43.29.Amgen, Inc. (NASDAQ: AMGN) second-quarter revenues rose 6% to $6.2 billion and non-GAAP EPS increased 7% to $4.25, ahead of the $3.82 consensus estimate. The company maintained its full-year revenue guidance and upwardly revised its non-GAAP EPS guidance.The stock moved down 1.48% to $251.50 in after-hours trading.Offerings Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) priced its underwritten public offering of 3.264 million shares of its common stock at $53 per share, for raising gross proceeds of about $173 million. The company said it intends to use the net proceeds of the offering to develop, test and manufacture the Company's LUNAR-COV19 vaccine candidate, among other things.The stock slid 5.40% to $52.60 in after-hours trading.Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) said it intends to offer shares of its common stock in an underwritten public offering. The net proceeds would be used to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes, it added.In after-hours trading, the stock was down 11.57% to 35 cents.ESSA Pharma Inc (NASDAQ: EPIX) said it has priced an underwritten public offering of 7.1 million shares at $6 per share, for generating net proceeds of $39 million. The net proceeds would be used for pre-clinical and clinical activities, chemistry, manufacturing and controls, R&D, as well as working capital and general corporate purposes, the company added.On The Radar Clinical Readouts AC Immune SA (NASDAQ: ACIU) is due to present at the AAIC key data on its alpha-synuclein-positron emission tomography tracer program along with a second oral presentation of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndrome.Earnings Boston Scientific Corporation (NYSE: BSX) (before the market open) Alkermes Plc (NASDAQ: ALKS) (before the market open) United Therapeutics Corporation (NASDAQ: UTHR) (before the market open) Hologic, Inc. (NASDAQ: HOLX) (after the close) Alimera Sciences Inc (NASDAQ: ALIM) (after the close) Merit Medical Systems, Inc. (NASDAQ: MMSI) (after the close) Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close) Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)See more from Benzinga * The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding * The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings * The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Alector (ALEC) Presents At Alzheimer's Association International Conference: AICC 2020 - Slideshow
- The following slide deck was published by Alector, Inc. in conjunction with this event..
- 07/29/2020
|
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
- * AL001 was generally safe and well-tolerated in Phase 1b study and after continuous dosing in 15 asymptomatic and symptomatic FTD-GRN participants in Phase 2 study * Treatment with AL001 in Phase 2 study resulted in sustained restoration of plasma progranulin levels in all FTD-GRN participants back to normal range and the majority of symptomatic FTD-GRN participants showed a decrease in plasma neurofilament light chain (NfL) levels from baseline * Pivotal Phase 3 study initiated in July 2020SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotemporal dementia with a progranulin gene (GRN) mutation (FTD-GRN). AL001 is the company’s wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain. The data were presented today at the virtual 2020 Alzheimer’s Association International Conference (AAIC) by Robert Paul, M.D., Ph.D., chief medical officer of Alector.Frontotemporal dementia is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis. There are multiple heritable forms of FTD, and FTD-GRN represents 5% to 10% of all people with FTD. There are currently no FDA-approved treatment options for FTD.“We continue to discover and develop therapies in pursuit of our goal to eradicate neurodegenerative diseases,” said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. “The encouraging results from the Phase 1b and Phase 2 studies of AL001 represent substantial progress. With our rapid initiation of a pivotal Phase 3 trial, we hope that it is only a matter of time before AL001 is the first treatment option for people living with this devastating disease.”The ongoing Phase 2, multicenter, open-label, study is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), fluid and imaging biomarkers and the effect on clinical outcome assessments of AL001. The Phase 2 study is expected to enroll up to 40 participants who will receive treatment with AL001 for up to 96 weeks. The study has completed enrollment of 10 symptomatic patients with FTD-GRN and 5 asymptomatic individuals carrying a GRN mutation. Enrollment for FTD patients with C9orf72 mutations is currently ongoing.Due to the COVID-19 pandemic, several clinical sites for the Phase 2 study were temporarily closed or conducted reduced or remote patient assessments during the evaluation period. As a result, some participants missed a dose of AL001 or missed clinical assessments during the treatment period. Alector is working closely with the sites, investigators and participants to manage future effects of the COVID-19 pandemic on the study.“AL001 was well-tolerated and caused sustained restoration of plasma progranulin levels in all FTD-GRN participants back to normal levels. These preliminary findings are encouraging and also suggest that long-term treatment with AL001 has the potential to slow disease progression in patients with FTD-GRN as measured by relevant disease biomarkers,” said Dr. Paul. “Although the COVID-19 pandemic impacted data collection for this initial analysis, we believe these early results are quite promising. We continue to advance the Phase 2 study and would like to thank the participants, their families and our study collaborators for their support in advancing AL001 forward.”A summary of the preliminary results from the Phase 2 study are as follows: * A total of 15 participants with symptomatic and asymptomatic FTD-GRN have been evaluated in the Phase 2 study as of May 14, 2020. * AL001 was observed to be generally safe and well-tolerated. There were no treatment-related serious adverse events observed in participants receiving AL001 treatment. * AL001 led to sustained restoration of plasma progranulin levels in all FTD-GRN participants back to the normal range. * Preliminary data from the symptomatic FTD-GRN participants showed a decrease in plasma NfL levels from baseline in the majority of participants at the last measured time point. * In the presented case study of a symptomatic FTD-GRN participant, with the longest continuous treatment with AL001 for over 28 weeks, treatment resulted in a sustained decrease in plasma NfL by 29% from baseline. These early data suggest that longer term treatment with AL001 could lead to sustained increase in PGRN and sustained reduction in plasma NfL over time. Alector plans to present additional Phase 2 data highlighting clinical and biomarker endpoints in the future.In July 2020, Alector announced that the first patient was dosed in INFRONT-3, a global, pivotal Phase 3 trial evaluating the efficacy and safety of AL001 in symptomatic and pre-symptomatic people with FTD-GRN. AL001 has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for FTD.About the AL001 Open-Label Phase 2 Clinical Study The AL001 Phase 2 clinical study is an ongoing, multicenter study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 administered intravenously in participants with a progranulin gene mutation (GRN) or C9orf72 mutation causative of frontotemporal dementia. The study is designed to assess the safety and tolerability of AL001 and measure the levels of progranulin, a disease specific biomarker, in plasma and in cerebrospinal fluid. Up to 40 patients will be enrolled and will receive treatment with AL001 for up to 96 weeks. For more information on the Phase 2 study, please visit www.clinicaltrials.gov.About Frontotemporal Dementia (FTD) Frontotemporal dementia is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis. It affects 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America. There are currently no FDA-approved treatments options for FTD.There are multiple heritable forms of FTD. In one form, FTD-GRN, people have a mutation in the progranulin gene. This population represents 5% to 10% of all people with FTD. Mutations in a single copy of a progranulin gene leads to a 50% or greater decrease in the level of progranulin protein and invariably leads to development of FTD. In another form, FTD-C9orf72, people with mutations in the chromosome 9 open reading frame 72 (C9orf72) gene can develop FTD, which represents approximately 5% to 10% of all people with FTD. FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43, which is also a hallmark in FTD-GRN. To date researchers have identified more than 120 inherited loss of function mutations in the progranulin gene that lead to FTD.About Alector Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company’s plans for and anticipated benefits and mechanism of the Company’s product candidates, the timing and objectives of the clinical studies and anticipated regulatory and development milestones. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports Alector files with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q that is filed with the Securities and Exchange Commission (“SEC”). Copies of reports filed with the SEC are posted on Alector’s website and are available from Alector without charge.Contacts Media Erica Jefferson Vice President, Communications and Public Affairs Alector, Inc. 301-928-4650 erica.jefferson@alector.com1AB Dan Budwick 973-271-6085 dan@1abmedia.com orInvestors: Alector, Inc. ir@alector.com
- 07/28/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
Stocks To Watch: Big Focus On Big Tech
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/25/2020
|
13Ds Filings
- Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies
- 07/24/2020
|
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
- * Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD-GRN gene mutation at multiple sites in the U.S., Europe and Australia * There are currently no FDA-approved treatments for frontotemporal dementia SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first patient in its pivotal Phase 3 clinical trial, named INFRONT-3, evaluating AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). AL001 is the company’s wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain. Frontotemporal Dementia (FTD) is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis. It affects 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are multiple heritable forms of FTD, and FTD-GRN patients represent 5% to 10% of all people with FTD. There are currently no approved treatments options available for FTD.“The initiation of our global pivotal Phase 3 trial of AL001 is a significant step towards achieving our mission of helping patients suffering from FTD and other neurodegenerative diseases,” said Robert Paul, M.D., Ph.D., chief medical officer of Alector. “Our Phase 3 study has been designed to measure slowing of disease progression in both symptomatic and pre-symptomatic FTD-GRN patients. We believe the INFRONT-3 trial will successfully demonstrate AL001’s ability to significantly alter the course of FTD and potentially transform the lives of people affected by this condition. We are incredibly grateful to the patients, healthcare professionals and clinical sites that participated during earlier phases of study, allowing us to rapidly progress to Phase 3 evaluation in less than two years.”The randomized, double-blind, placebo-controlled trial will enroll up to 180 FTD-GRN mutation carriers across approximately 50 sites in the United States, Europe and Australia. Symptomatic and pre-symptomatic participants will be randomized to receive AL001 or placebo intravenously every four weeks. Participants will also be given the option to continue receiving treatment in an open-label extension study. The primary endpoint of the pivotal Phase 3 trial is to measure the effect of AL001 on clinical decline by utilizing the CDR® plus NACC FTLD-SB assessment, which evaluates clinical impairments in behavior, language, memory, judgment, and functional activities in trial participants. In addition, the trial will assess secondary clinical endpoints, multiple biomarkers and safety.To learn more about the Phase 3 trial, please visit https://clinicaltrials.gov/.About AL001 AL001 is a wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease, and Parkinson’s disease. AL001 aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. AL001 was discovered and engineered in collaborative effort between Alector and Adimab, LLC.AL001 has received Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN from the U.S. Food and Drug Administration.About Frontotemporal Dementia (FTD) FTD is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis. It affects 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are currently no FDA-approved treatments options for FTD.There are multiple heritable forms of FTD. In one form, FTD-GRN, people have a mutation in the progranulin gene. This population represents 5% to 10% of all people with FTD. Mutations in a single copy of progranulin gene (GRN) leads to a 50% or greater decrease in the level of progranulin and invariably leads to development of FTD. In another form, FTD-C9orf72, people with mutations in the C9orf72 gene can develop FTD, which represents approximately 5% to 10% of all people with FTD. FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43, which is also a hallmark pathology found in FTD-GRN. About Alector Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to the Company’s plans for and anticipated benefits and mechanism of the Company’s product candidates, the timing and objectives of the Company’s clinical studies and anticipated regulatory and development milestones, Alector and its business as set forth in Alector’s Annual Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 13, 2020, as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.Contacts: Media Erica Jefferson Vice President, Communications and Public Affairs Alector, Inc. 301-928-4650 erica.jefferson@alector.com1AB Dan Budwick 973-271-6085 dan@1abmedia.comorInvestors: Alector, Inc. ir@alector.com
- 07/24/2020
|
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference
- SOUTH SAN FRANCISCO, Calif., July 21, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company.
- 07/21/2020
|
Should You Take Comfort From Insider Transactions At Alector, Inc. (NASDAQ:ALEC)?
- We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- 07/15/2020
|
Hedge Funds Keep Buying Alector, Inc. (ALEC)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/28/2020
|
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine
- Chronic treatment enhanced neuroprotective microglia, reduced neuronal damage, tempered microglial inflammatory response and contained toxic beta amyloid plaques in a mouse model of Alzheimer’s disease. The paper, “Anti-human TREM2 antibody induces microglia proliferation and reduces pathology in an Alzheimer's Disease model,” was carried out in collaboration with Marco Colonna, M.D. at Washington University in St. Louis and can be accessed here.
- 06/25/2020
|
Women are more prone to Alzheimer’s disease 'due to the menopause', study warns
- Scientists from Weill Cornell Graduate School of Medical Sciences in New York have revealed that women are more prone to Alzheimer’s disease than men due to the menopause
- 06/24/2020
|
Insider Selling: Alector Inc (NASDAQ:ALEC) Insider Sells $296,100.00 in Stock
- Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 10,000 shares of Alector stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $29.61, for a total transaction of $296,100.00. Following the transaction, the insider now owns 227,628 shares of the company’s stock, valued at $6,740,065.08. The sale was disclosed […]
- 06/20/2020
|
NortonLifeLock and Bancorp See Activist Actions
- Starboard Value sold 10.9 million NortonLifeLock shares to trim its stake in the cybersecurity firm to 5.6%. Castle Creek raised its stake in fintech firm Bancorp to 6.3%.
- 06/12/2020
|
Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., June 03, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of.
- 06/03/2020
|
Analysts Have Made A Financial Statement On Alector, Inc.'s (NASDAQ:ALEC) First-Quarter Report
- The analysts might have been a bit too bullish on Alector, Inc. (NASDAQ:ALEC), given that the company fell short of...
- 05/16/2020
|
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2020
|
Alector Reports 2020 First Quarter Financial Results and Business Highlights
- “Our COVID-19 task force and the entire Alector team continues to focus on initiating a pivotal Phase 3 study of AL001 in FTD-GRN patients and a Phase 2 study of AL002 in Alzheimer’s disease patients in 2020.” Alector is actively monitoring the evolving impact of COVID-19 on its operations and clinical trials, with a primary focus on the health and safety of employees, clinical trial participants, and clinical trial site teams.
- 05/13/2020
|
Alector to Present at the Bank of America Securities Virtual Health Care Conference
- SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz.
- 05/07/2020
|
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% (NEWS-PORTAL)
- Times are changing on Wall Street. The COVID-19 pandemic and the havoc it’s wreaking have induced levels of return dispersion unlike anything witnessed since the Great Depression, but this isn’t necessarily a bad thing for investors. Up until recently, the decade had seen low return dispersion, or the variation among stocks’ returns was relatively limited. Given the narrower range of returns, it became more challenging to zero in on the names escaping the attention of other stock pickers. As a result, there was a surge in index-tracking passive funds, and several active managers found it difficult to deliver wins. Enter COVID-19-related economic uncertainty. Not only have global markets been rattled, but corporate profits have also been pushed lower. In addition, valuations have been propelled in every possible direction. This in turn has caused stock returns to diverge the most since the recession in 2007-2009, notes Goldman Sachs strategist Ryan Hammond. Hammond argues that return dispersion comes down to two factors, stock correlations and market volatility, with it at the highest levels when correlations fall and volatility is heightened. While volatility was primarily to blame, the Goldman Sachs strategist points out that lower correlations usually come hand in hand with declining volatility, and thus, he expects the dispersion to persist. This presents investors with an exciting opportunity to scope out the names poised to outperform, especially in the midst of earnings season. Bearing this in mind, we used TipRanks’ database to evaluate the long-term growth prospects of three stocks in Goldman Sachs’ coverage universe. According to the platform, substantial gains could be in store for each ticker. We’re talking about over 30% here. Let’s jump right in. Alector Inc. (ALEC) The first of Goldman Sachs’ picks is Alector, a biotech name that uses the power of the immune system to strengthen pipeline innovation, de-risk clinical programs and advance therapies to treat neurodegenerative and rare, orphan neurological diseases. Even though 2020 has already seen shares climb 40% higher, the firm believes there’s plenty of fuel left in the tank. Writing for Goldman Sachs, four-star analyst Graig Suvannavejh calls the company a “leader in the rapidly emerging I-N space.” To back up this claim, he points to ALEC’s significant focus on therapies that target neurodegeneration (NDG), a space with a very high unmet medical need. This area includes diseases like Alzheimer’s disease (AD), Parkinson’s disease, ALS as well as others. Additionally, the fact that its targets are genetically defined could boost overall probabilities of success (POS) and its diverse portfolio of earlier-stage assets gives it more pipeline optionality. When it comes to the AD opportunity specifically, Suvannavejh likes what he’s seeing. “We favor ALEC for its prospects for Phase 2-ready AL002 and AL003, antibodies directed against TREM2 and CD33/SIGLEC 3, respectively, for AD, which are partnered with AbbVie, and, given the extreme unmet medical need in AD, we model $7.5 billion and $5.9 billion, respectively in risk-unadjusted peak year sales,” he commented. That being said, for 2020, Suvannavejh argues that ALEC’s growth story will be centered around AL001, its sorting receptor that regulates levels of progranulin (PGRN) in plasma and the brain, in frontotemporal dementia (FTD), with a pivotal trial slated for this calendar year. He noted, “With that in mind, and incremental AL001 data updates expected this year, we see opportunities for positive share inflection from current levels...we see another meaningful ($1.8 billion peak unadjusted sales) and near-term (2024 estimated U.S. launch) revenue opportunity for ALEC, given the potential for ALEC to enter the market ahead of its competitors in the FTD space...” Based on all of the above, Suvannavejh joined the bulls. In addition to initiating his coverage with a Buy rating, he put a $32 price target on the stock. This implies shares could surge 32% in the next twelve months. (To watch Suvannavejh’s track record, click here) What does the rest of the Street have to say? It turns out that other analysts are on the same page. With 100% Street support, or 6 Buy ratings to be exact, the message is clear: ALEC is a Strong Buy. Not to mention the $36.20 average price target puts the upside potential at 50%. (See Alector stock analysis on TipRanks)Adverum Biotechnologies (ADVM) Another biotech company, Adverum is focused on developing ADVM-022, its novel anti-VEGF gene therapy candidate for chronic, degenerative eye diseases. Shares are up 41% in the last month, but there’s still room for ADVM to grow, according to Goldman Sachs. Graig Suvannavejh, who also covers ALEC, argues that ADVM-022 could be “transformative” based on the current nature of the anti-VEGF space. Expounding on this, he stated, “While the anti-VEGF market is large and well-established (c.$11.5 billion in 2019 global sales for current branded products), current treatment with anti-VEGF is sharply limited by the high frequency of direct injections into the eye. This results in lack of compliance, especially given an older patient population, which limits effective treatment.” Looking at ADVM-022, it could be the ideal treatment for retinal disease thanks to the AAV.7m8 vector, which was designed via directed evolution for high infectivity and preferential transduction of retinal cells. “As a result (and in contrast to a chief competitor), ADVM-022 can be delivered via IVT injection, thereby in our view, facilitating the potential of a seamless transition into the current treatment paradigm. Moreover, ADVM-022’s transgene has shown proven real-world efficacy, which serves, in our view, to partially de-risk its still early-stage clinical development,” Suvannavejh said. Even with the currently approved branded therapies, Eylea and Lucentis, set to lose exclusivity in the coming years, Suvannavejh believes the market will most likely put a price premium on differentiated therapies, which bodes well for ADVM. Additionally, while ADVM-022 isn’t expected to launch commercially until 2027, the analyst’s risk-adjusted revenue estimates exceed the consensus by 2033. The candidate could also potentially be evaluated for use in other indications. This seals the deal for Suvannavejh. To kick off his coverage, he assigned a Buy rating and $17 price target. Should this target be met, a twelve-month gain of 42% could be in the cards. ADVM has also received support from other Wall Street analysts. 5 Buys and 1 Hold were issued in the last three months, making the consensus rating a Strong Buy. At $17, the average price target matches Suvannavejh’s. (See Adverum stock analysis on TipRanks)Sogou Inc. (SOGO) Moving into a different industry entirely, we come across Chinese search engine Sogou. It’s no secret that the company has underperformed as of late, but Goldman Sachs thinks the tide could be turning. Ahead of its Q1 earnings release on May 4, four-star analyst Piyush Mubayi acknowledges that SOGO has had a rough going recently. He predicts that search-related revenues will dip 4%/3% year-over-year in Q1/Q2, compared to the 19%/11% year-over-year Q1/Q2 declines at Baidu Core Search. It should also be noted that the analyst cut the 12-month forward target multiple of SOGO’s core business from 9x to 8x, compared to 10x at Baidu, to account for the slower revenue growth outlook. Even though Mubayi believes the tech company will continue to face macro headwinds in the near-term as well as fierce competition in the online advertising industry in the long-term, there are still reasons to be optimistic. “The relatively more resilient growth outlook in the near term is primarily due to 1) smaller search revenue scale (at ~1/9 of that at Baidu in 2019) and 2) lower exposure to healthcare vertical,” Mubayi explained. Adding to the good news, SOGO has remained stable in the mobile query space. According to CTR, looking at mobile queries in December 2019, the company controlled 18.3% of the market in China, down only slightly from 18.5% market share in December 2018. As a result, Mubayi expects that the second largest search player in China will be able to maintain its control of the market. When it comes to advertising, Mubayi commented, “While we remain cautious on the overall advertising industry into 2020E and the increasing competition in ad budget allocation to search in the long term, we think the risk reward at current stock price is to the upside.” All of this prompted Mubayi to upgrade the rating from a Neutral to a Buy. Given the $4.50 price target, shares could rise 33% in the coming twelve months. (To watch Mubayi’s track record, click here) Judging by the overall consensus breakdown, it has been relatively quiet with respect to other analyst activity. Only one other review has been published recently, with the analyst giving the stock a Hold recommendation. Based on 1 Buy and 1 Hold, SOGO earns a Moderate Buy consensus rating. In addition, shares could surge 32% thanks to the $4.45 average price target. (See Sogou price targets and analyst ratings on TipRanks)
- 05/04/2020
|
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30%
- Times are changing on Wall Street. The COVID-19 pandemic and the havoc it’s wreaking have induced levels of return dispersion unlike anything witnessed since the Great Depression, but this isn’t necessarily a bad thing for investors. Up until recently, the decade had seen low return dispersion, or the variation among stocks’ returns was relatively limited. Given the narrower range of returns, it became more challenging to zero in on the names escaping the attention of other stock pickers. As a result, there was a surge in index-tracking passive funds, and several active managers found it difficult to deliver wins. Enter COVID-19-related economic uncertainty. Not only have global markets been rattled, but corporate profits have also been pushed lower. In addition, valuations have been propelled in every possible direction. This in turn has caused stock returns to diverge the most since the recession in 2007-2009, notes Goldman Sachs strategist Ryan Hammond. Hammond argues that return dispersion comes down to two factors, stock correlations and market volatility, with it at the highest levels when correlations fall and volatility is heightened. While volatility was primarily to blame, the Goldman Sachs strategist points out that lower correlations usually come hand in hand with declining volatility, and thus, he expects the dispersion to persist. This presents investors with an exciting opportunity to scope out the names poised to outperform, especially in the midst of earnings season. Bearing this in mind, we used TipRanks’ database to evaluate the long-term growth prospects of three stocks in Goldman Sachs’ coverage universe. According to the platform, substantial gains could be in store for each ticker. We’re talking about over 30% here. Let’s jump right in. Alector Inc. (ALEC) The first of Goldman Sachs’ picks is Alector, a biotech name that uses the power of the immune system to strengthen pipeline innovation, de-risk clinical programs and advance therapies to treat neurodegenerative and rare, orphan neurological diseases. Even though 2020 has already seen shares climb 40% higher, the firm believes there’s plenty of fuel left in the tank. Writing for Goldman Sachs, four-star analyst Graig Suvannavejh calls the company a “leader in the rapidly emerging I-N space.” To back up this claim, he points to ALEC’s significant focus on therapies that target neurodegeneration (NDG), a space with a very high unmet medical need. This area includes diseases like Alzheimer’s disease (AD), Parkinson’s disease, ALS as well as others. Additionally, the fact that its targets are genetically defined could boost overall probabilities of success (POS) and its diverse portfolio of earlier-stage assets gives it more pipeline optionality. When it comes to the AD opportunity specifically, Suvannavejh likes what he’s seeing. “We favor ALEC for its prospects for Phase 2-ready AL002 and AL003, antibodies directed against TREM2 and CD33/SIGLEC 3, respectively, for AD, which are partnered with AbbVie, and, given the extreme unmet medical need in AD, we model $7.5 billion and $5.9 billion, respectively in risk-unadjusted peak year sales,” he commented. That being said, for 2020, Suvannavejh argues that ALEC’s growth story will be centered around AL001, its sorting receptor that regulates levels of progranulin (PGRN) in plasma and the brain, in frontotemporal dementia (FTD), with a pivotal trial slated for this calendar year. He noted, “With that in mind, and incremental AL001 data updates expected this year, we see opportunities for positive share inflection from current levels...we see another meaningful ($1.8 billion peak unadjusted sales) and near-term (2024 estimated U.S. launch) revenue opportunity for ALEC, given the potential for ALEC to enter the market ahead of its competitors in the FTD space...” Based on all of the above, Suvannavejh joined the bulls. In addition to initiating his coverage with a Buy rating, he put a $32 price target on the stock. This implies shares could surge 32% in the next twelve months. (To watch Suvannavejh’s track record, click here) What does the rest of the Street have to say? It turns out that other analysts are on the same page. With 100% Street support, or 6 Buy ratings to be exact, the message is clear: ALEC is a Strong Buy. Not to mention the $36.20 average price target puts the upside potential at 50%. (See Alector stock analysis on TipRanks)Adverum Biotechnologies (ADVM) Another biotech company, Adverum is focused on developing ADVM-022, its novel anti-VEGF gene therapy candidate for chronic, degenerative eye diseases. Shares are up 41% in the last month, but there’s still room for ADVM to grow, according to Goldman Sachs. Graig Suvannavejh, who also covers ALEC, argues that ADVM-022 could be “transformative” based on the current nature of the anti-VEGF space. Expounding on this, he stated, “While the anti-VEGF market is large and well-established (c.$11.5 billion in 2019 global sales for current branded products), current treatment with anti-VEGF is sharply limited by the high frequency of direct injections into the eye. This results in lack of compliance, especially given an older patient population, which limits effective treatment.” Looking at ADVM-022, it could be the ideal treatment for retinal disease thanks to the AAV.7m8 vector, which was designed via directed evolution for high infectivity and preferential transduction of retinal cells. “As a result (and in contrast to a chief competitor), ADVM-022 can be delivered via IVT injection, thereby in our view, facilitating the potential of a seamless transition into the current treatment paradigm. Moreover, ADVM-022’s transgene has shown proven real-world efficacy, which serves, in our view, to partially de-risk its still early-stage clinical development,” Suvannavejh said. Even with the currently approved branded therapies, Eylea and Lucentis, set to lose exclusivity in the coming years, Suvannavejh believes the market will most likely put a price premium on differentiated therapies, which bodes well for ADVM. Additionally, while ADVM-022 isn’t expected to launch commercially until 2027, the analyst’s risk-adjusted revenue estimates exceed the consensus by 2033. The candidate could also potentially be evaluated for use in other indications. This seals the deal for Suvannavejh. To kick off his coverage, he assigned a Buy rating and $17 price target. Should this target be met, a twelve-month gain of 42% could be in the cards. ADVM has also received support from other Wall Street analysts. 5 Buys and 1 Hold were issued in the last three months, making the consensus rating a Strong Buy. At $17, the average price target matches Suvannavejh’s. (See Adverum stock analysis on TipRanks)Sogou Inc. (SOGO) Moving into a different industry entirely, we come across Chinese search engine Sogou. It’s no secret that the company has underperformed as of late, but Goldman Sachs thinks the tide could be turning. Ahead of its Q1 earnings release on May 4, four-star analyst Piyush Mubayi acknowledges that SOGO has had a rough going recently. He predicts that search-related revenues will dip 4%/3% year-over-year in Q1/Q2, compared to the 19%/11% year-over-year Q1/Q2 declines at Baidu Core Search. It should also be noted that the analyst cut the 12-month forward target multiple of SOGO’s core business from 9x to 8x, compared to 10x at Baidu, to account for the slower revenue growth outlook. Even though Mubayi believes the tech company will continue to face macro headwinds in the near-term as well as fierce competition in the online advertising industry in the long-term, there are still reasons to be optimistic. “The relatively more resilient growth outlook in the near term is primarily due to 1) smaller search revenue scale (at ~1/9 of that at Baidu in 2019) and 2) lower exposure to healthcare vertical,” Mubayi explained. Adding to the good news, SOGO has remained stable in the mobile query space. According to CTR, looking at mobile queries in December 2019, the company controlled 18.3% of the market in China, down only slightly from 18.5% market share in December 2018. As a result, Mubayi expects that the second largest search player in China will be able to maintain its control of the market. When it comes to advertising, Mubayi commented, “While we remain cautious on the overall advertising industry into 2020E and the increasing competition in ad budget allocation to search in the long term, we think the risk reward at current stock price is to the upside.” All of this prompted Mubayi to upgrade the rating from a Neutral to a Buy. Given the $4.50 price target, shares could rise 33% in the coming twelve months. (To watch Mubayi’s track record, click here) Judging by the overall consensus breakdown, it has been relatively quiet with respect to other analyst activity. Only one other review has been published recently, with the analyst giving the stock a Hold recommendation. Based on 1 Buy and 1 Hold, SOGO earns a Moderate Buy consensus rating. In addition, shares could surge 32% thanks to the $4.45 average price target. (See Sogou price targets and analyst ratings on TipRanks)
- 05/03/2020
|
Alector Inc (NASDAQ:ALEC) Given Average Recommendation of "Buy" by Analysts
- Shares of Alector Inc (NASDAQ:ALEC) have received a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated […]
- 05/02/2020
|
Bank of America Corp DE Increases Position in Alector Inc (NASDAQ:ALEC)
- Bank of America Corp DE raised its holdings in shares of Alector Inc (NASDAQ:ALEC) by 91.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,325 shares of the company’s stock after buying an additional 13,067 shares during the period. Bank of […]
- 04/29/2020
|
Wells softens view on Edwards Lifesciences in premarket analyst action
- Adverum Biotechnologies (NASDAQ:ADVM) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs.Alector (NASDAQ:ALEC) initiated with Buy rating and $32 (21% upside) price target at
- 04/28/2020
|
Alector (NASDAQ:ALEC) Shares Up 5.5%
- Alector Inc (NASDAQ:ALEC)’s stock price shot up 5.5% on Friday . The company traded as high as $25.60 and last traded at $25.32, 362,895 shares were traded during trading. A decline of 42% from the average session volume of 622,223 shares. The stock had previously closed at $24.01. A number of research firms have weighed […]
- 04/26/2020
|
Dementia warning: Certain foods that form the basis of your diet may increase your risk
- DEMENTIA is a debilitating condition which currently has no cure. But a person may be able to reduce their risk of developing the condition - avoiding certain combinations of food could help.
- 04/23/2020
|
Alector (NASDAQ:ALEC) Upgraded to "Buy" at BidaskClub
- Alector (NASDAQ:ALEC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, BidAskClub reports. Several other equities research analysts have also recently commented on ALEC. Citigroup began coverage on shares of Alector in a research report on Thursday, March 5th. They set […]
- 04/23/2020
|
Bank of New York Mellon Corp Buys 20,080 Shares of Alector Inc (NASDAQ:ALEC)
- Bank of New York Mellon Corp increased its stake in shares of Alector Inc (NASDAQ:ALEC) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,011 shares of the company’s stock after buying an additional 20,080 shares during the quarter. Bank […]
- 04/22/2020
|
Alector Inc (NASDAQ:ALEC) Short Interest Update
- Alector Inc (NASDAQ:ALEC) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 5,380,000 shares, a drop of 8.3% from the March 15th total of 5,870,000 shares. Based on an average daily volume of 671,600 shares, the days-to-cover ratio is presently 8.0 days. Currently, […]
- 04/21/2020
|
Alliancebernstein L.P. Has $519,000 Stake in Alector Inc (NASDAQ:ALEC)
- Alliancebernstein L.P. boosted its position in Alector Inc (NASDAQ:ALEC) by 22.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 30,100 shares of the company’s stock after acquiring an additional 5,600 shares during the period. Alliancebernstein L.P.’s holdings in Alector were worth $519,000 as of its most […]
- 04/20/2020
|
Alector (NASDAQ:ALEC) PT Raised to $29.00 at Morgan Stanley
- Alector (NASDAQ:ALEC) had its target price boosted by Morgan Stanley from $27.00 to $29.00 in a research report released on Wednesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Alector from […]
- 04/19/2020
|
Alector Inc (NASDAQ:ALEC) Insider Sells $222,700.00 in Stock
- Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 10,000 shares of Alector stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $22.27, for a total value of $222,700.00. Following the completion of the transaction, the insider now directly owns 243,719 shares of the company’s stock, valued at $5,427,622.13. […]
- 04/19/2020
|
Alector Inc (NASDAQ:ALEC) Major Shareholder Orbimed Advisors Llc Sells 23,231 Shares
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 23,231 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $23.52, for a total value of $546,393.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed […]
- 04/18/2020
|
Insider Selling: Alector Inc (NASDAQ:ALEC) Major Shareholder Sells 62,183 Shares of Stock
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 62,183 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $23.53, for a total value of $1,463,165.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is […]
- 04/18/2020
|
Alector (ALEC) Gets a Buy Rating from Morgan Stanley
- In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Alector (ALEC), with a price target of $29.00. The company's
- 04/15/2020
|
Alector (NASDAQ:ALEC) Downgraded by BidaskClub
- Alector (NASDAQ:ALEC) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Several other research firms also recently weighed in on ALEC. Stifel Nicolaus started coverage on Alector in a research note on Tuesday, February 18th. They […]
- 04/15/2020
|
Alector, Inc. (NASDAQ:ALEC) Analysts Just Trimmed Their Revenue Forecasts By 21%
- Today is shaping up negative for Alector, Inc. (NASDAQ:ALEC) shareholders, with the analysts delivering a substantial...
- 04/12/2020
|
Orbimed Advisors Llc Sells 9,170 Shares of Alector Inc (NASDAQ:ALEC) Stock
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 9,170 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $23.10, for a total value of $211,827.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. […]
- 04/11/2020
|
Orbimed Advisors Llc Sells 288,101 Shares of Alector Inc (NASDAQ:ALEC) Stock
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 288,101 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $23.79, for a total value of $6,853,922.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed […]
- 04/11/2020
|
Franklin Resources Inc. Raises Stock Holdings in Alector Inc (NASDAQ:ALEC)
- Franklin Resources Inc. grew its stake in shares of Alector Inc (NASDAQ:ALEC) by 41.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 794,400 shares of the company’s stock after acquiring an additional 234,000 shares during the quarter. Franklin Resources Inc. […]
- 04/09/2020
|
Maybe We Can Climb The Great Wall Of Worry
- The short- and long-term outlook is good, but mid-term risks are high. Here's what you can do now. Healthcare, consumer goods, and financials are the best secto
- 04/07/2020
|
9 Stocks to Buy to Profit off the Baby Boomer Generation
- While most investors may focus exclusively on the millennials, it’s the baby boomers that could be the most relevant for Wall Street.
- 04/07/2020
|
Goldman Sachs Group Inc. Has $8.03 Million Stock Holdings in Alector Inc (NASDAQ:ALEC)
- Goldman Sachs Group Inc. boosted its stake in shares of Alector Inc (NASDAQ:ALEC) by 13.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 465,937 shares of the company’s stock after buying an additional 54,027 shares during the period. Goldman Sachs Group Inc. owned approximately 0.68% of […]
- 04/07/2020
|
Alector Inc (NASDAQ:ALEC) Given Average Recommendation of "Buy" by Brokerages
- Alector Inc (NASDAQ:ALEC) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on […]
- 04/07/2020
|
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
- Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- 04/06/2020
|
Credit Suisse AG Raises Stake in Alector Inc (NASDAQ:ALEC)
- Credit Suisse AG raised its position in Alector Inc (NASDAQ:ALEC) by 22.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,913 shares of the company’s stock after acquiring an additional 6,299 shares during the quarter. Credit Suisse AG’s holdings in Alector were […]
- 04/06/2020
|
Insider Selling: Alector Inc (NASDAQ:ALEC) Major Shareholder Sells $6,125,000.00 in Stock
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 250,000 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $24.50, for a total transaction of $6,125,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC […]
- 04/05/2020
|
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
- Is (ALEC) Outperforming Other Medical Stocks This Year?
- 04/02/2020
|
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
- Is (ALEC) Outperforming Other Medical Stocks This Year?
- 04/02/2020
|
Growth Investors: Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 36%
- Shareholders in Alector, Inc. (NASDAQ:ALEC) may be thrilled to learn that the analysts have just delivered a major...
- 03/31/2020
|
Week In Review: Abbisko Raises $70 Million To Develop Cancer Drug Candidates
- Laekna Therapeutics Shanghai acquired global rights to Novartis' anti-PD-L1 antibody. Tyligand Bioscience acquired exclusive China rights to onapristone ER from
- 03/30/2020
|
Need To Know: Analysts Are Much More Bullish On Alector, Inc. (NASDAQ:ALEC) Revenues
- Alector, Inc. (NASDAQ:ALEC) shareholders will have a reason to smile today, with the analysts making substantial...
- 03/29/2020
|
Bank of Montreal Can Increases Stock Holdings in Alector Inc (NASDAQ:ALEC)
- Bank of Montreal Can boosted its position in Alector Inc (NASDAQ:ALEC) by 44.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,826 shares of the company’s stock after purchasing an additional 1,169 shares during the period. Bank of Montreal Can’s holdings in Alector were worth […]
- 03/27/2020
|
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The Dumps (Biotech stocks that hit 52-week lows March 25.) * Anixa Biosciences Inc (NASDAQ: ANIX)
- 03/26/2020
|
BidaskClub Lowers Alector (NASDAQ:ALEC) to Buy
- Alector (NASDAQ:ALEC) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. ALEC has been the topic of several other research reports. Stifel Nicolaus initiated coverage on shares of Alector in a research note on Tuesday, February 18th. They […]
- 03/26/2020
|
Earnings Beat: Alector, Inc. (NASDAQ:ALEC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
- It's been a mediocre week for Alector, Inc. (NASDAQ:ALEC) shareholders, with the stock dropping 16% to US$23.45 in the...
- 03/26/2020
|
Analysts Are Upgrading Alector, Inc. (NASDAQ:ALEC) After Its Latest Results
- There's been a notable change in appetite for Alector, Inc. (NASDAQ:ALEC) shares in the week since its full-year...
- 03/26/2020
|
Alector Inc (NASDAQ:ALEC) Major Shareholder Sells $380,277.90 in Stock
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 14,598 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $26.05, for a total transaction of $380,277.90. The transaction was disclosed in a filing with the SEC, which is available through the […]
- 03/26/2020
|
Alector Inc (NASDAQ:ALEC) Major Shareholder Orbimed Advisors Llc Sells 56,411 Shares
- Alector Inc (NASDAQ:ALEC) major shareholder Orbimed Advisors Llc sold 56,411 shares of the company’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $24.66, for a total transaction of $1,391,095.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through […]
- 03/26/2020
|
BRIEF-Alector Inc - We Will Continue To Develop Al008 Globally
|
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
- Alector, Inc. (ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that harness the innate immune system, and Innovent Biologics, a leading Chinese biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, jointly announced today the execution of a regional licensing agreement to develop and commercialize AL008 for oncology indications in China. AL008 is a novel antibody product candidate targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system.
- 03/25/2020
|
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
- AL008 is Alector’s dual function SIRP-alpha inhibitor and Fc gamma receptor activator antibody targeting the innate immune system for oncology...
- 03/25/2020
|
Cowen & Co. Sticks to Their Buy Rating for Alector (ALEC)
- In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Alector (ALEC). The company's shares closed last Monday at
- 03/24/2020
|
Cowen & Co. Sticks to Their Buy Rating for Alector (ALEC)
- In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Alector (ALEC – Research
- 03/24/2020
|
BRIEF-Alector Reports Q4 Loss Per Share Of $0.45
|
Alector (ALEC) Reports Q4 Loss, Misses Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/24/2020
|
Alector (ALEC) Reports Q4 Loss, Misses Revenue Estimates
- Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 03/24/2020
|
Alector: 4Q Earnings Snapshot
- SOUTH SAN FRANCISCO, Calif. (AP) _ Alector Inc. (ALEC) on Tuesday reported a loss of $30.5 million in its fourth quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 45 cents.
The results missed Wall
- 03/24/2020
|
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights
- Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019 On track to initiate pivotal Phase 3 trial.
- 03/24/2020
|
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights
- Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019 On track to initiate...
- 03/24/2020
|
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
- Alector, Inc. (ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is the David H. Koch Chair Professor of Engineering and Department Head, Chemical Engineering at the Massachusetts Institute of Technology (MIT), a member of MIT’s Koch Institute for Integrative Cancer Research and a founding member of the MIT Institute for Soldier Nanotechnology.
- 03/23/2020
|
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
- SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the...
- 03/23/2020
|
ProShare Advisors LLC Makes New Investment in Alector Inc (NASDAQ:ALEC)
- ProShare Advisors LLC bought a new position in Alector Inc (NASDAQ:ALEC) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,012 shares of the company’s stock, valued at approximately $328,000. Other hedge funds also recently modified their holdings of the company. Barclays PLC grew its stake […]
- 03/23/2020
|
Alector Inc (NASDAQ:ALEC) Holdings Raised by Citigroup Inc.
- Citigroup Inc. grew its stake in shares of Alector Inc (NASDAQ:ALEC) by 1,411.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,232 shares of the company’s stock after purchasing an additional 25,430 shares during the period. Citigroup Inc.’s holdings […]
- 03/22/2020
|
Zacks Investment Research Upgrades Alector (NASDAQ:ALEC) to Buy
- Zacks Investment Research upgraded shares of Alector (NASDAQ:ALEC) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. They currently have $26.00 price objective on the stock. According to Zacks, “Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment […]
- 03/21/2020
|
Robert Paul Sells 10,000 Shares of Alector Inc (NASDAQ:ALEC) Stock
- Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 10,000 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $22.93, for a total transaction of $229,300.00. Following the transaction, the insider now owns 262,238 shares in the company, valued at approximately $6,013,117.34. The sale […]
- 03/19/2020
|
Alector (NASDAQ:ALEC) Shares Down 11.1% After Insider Selling
- Alector Inc (NASDAQ:ALEC)’s share price dropped 11.1% during trading on Wednesday following insider selling activity. The stock traded as low as $24.00 and last traded at $25.04, approximately 947,623 shares changed hands during mid-day trading. An increase of 40% from the average daily volume of 678,531 shares. The stock had previously closed at $28.18. Specifically, […]
- 03/19/2020
|
Alector (ALEC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/17/2020
|
Alector (ALEC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/17/2020
|
What Makes Alector (ALEC) a New Buy Stock
- Alector (ALEC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/17/2020
|
What Makes Alector (ALEC) a New Buy Stock
- Alector (ALEC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/17/2020
|
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
- Is (ALEC) Outperforming Other Medical Stocks This Year?
- 03/17/2020
|
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
- Is (ALEC) Outperforming Other Medical Stocks This Year?
- 03/17/2020
|
Franklin Resources Inc. Has $13.69 Million Stake in Alector Inc (NASDAQ:ALEC)
- Franklin Resources Inc. grew its position in Alector Inc (NASDAQ:ALEC) by 41.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 794,400 shares of the company’s stock after purchasing an additional 234,000 shares during the quarter. Franklin Resources Inc.’s holdings in Alector were […]
- 03/17/2020
|
Charles Schwab Investment Management Inc. Has $3.14 Million Stock Holdings in Alector Inc (NASDAQ:ALEC)
- Charles Schwab Investment Management Inc. grew its stake in Alector Inc (NASDAQ:ALEC) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 182,374 shares of the company’s stock after buying an additional 4,022 shares during the period. Charles Schwab Investment Management […]
- 03/17/2020
|
Brokerages Set Alector Inc (NASDAQ:ALEC) Target Price at $28.00
- Alector Inc (NASDAQ:ALEC) has earned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their […]
- 03/16/2020
|
Barclays PLC Buys 23,466 Shares of Alector Inc (NASDAQ:ALEC)
- Barclays PLC boosted its stake in shares of Alector Inc (NASDAQ:ALEC) by 91.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,063 shares of the company’s stock after acquiring an additional 23,466 shares during the quarter. Barclays PLC owned 0.07% […]
- 03/12/2020
|
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?
- Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.
- 03/11/2020
|
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?
- Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.
- 03/11/2020
|
Can You Imagine How Alector’s (NASDAQ:ALEC) Shareholders Feel About The 65% Share Price Increase?
- The Alector, Inc. (NASDAQ:ALEC) share price has had a bad week, falling 14%. But that doesn't change the reality that...
- 03/11/2020
|
Rhumbline Advisers Purchases 1,108 Shares of Alector Inc (NASDAQ:ALEC)
- Rhumbline Advisers grew its position in Alector Inc (NASDAQ:ALEC) by 3.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,937 shares of the company’s stock after acquiring an additional 1,108 shares during the period. Rhumbline Advisers’ holdings in Alector […]
- 03/08/2020
|
New York State Common Retirement Fund Boosts Position in Alector Inc (NASDAQ:ALEC)
- New York State Common Retirement Fund raised its position in Alector Inc (NASDAQ:ALEC) by 2.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 27,200 shares of the company’s stock after purchasing an additional 700 shares during the period. New York State Common Retirement Fund’s holdings in Alector […]
- 03/08/2020
|
Critical Survey: Alector (NASDAQ:ALEC) versus Genocea Biosciences (NASDAQ:GNCA)
- Alector (NASDAQ:ALEC) and Genocea Biosciences (NASDAQ:GNCA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Valuation & Earnings This table compares Alector and Genocea Biosciences’ gross revenue, earnings per share (EPS) and […]
- 03/07/2020
|
Dave & Busters, International Flavors, Trinity Industries, 13D Filings
- Kohlberg Kravis Roberts increased its stake in casual dining and entertainment chain Dave & Busters.
- 03/07/2020
|
Goldman likes GW Pharma in premarket analyst action
- ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup.Alector (NASDAQ:ALEC) initiated with Buy rating and $40 (36% upside) price target at Citi.
- 03/06/2020
|
ValuEngine Upgrades Alector (NASDAQ:ALEC) to Hold
- Alector (NASDAQ:ALEC) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report released on Tuesday, ValuEngine reports. Several other equities analysts have also commented on the company. Barclays began coverage on Alector in a report on Thursday, February 27th. They issued an “overweight” rating on the stock. Zacks Investment Research […]
- 03/03/2020
|
Alector (NASDAQ:ALEC) Earns Overweight Rating from Analysts at Barclays
- Barclays initiated coverage on shares of Alector (NASDAQ:ALEC) in a research report released on Thursday morning, The Fly reports. The firm issued an overweight rating on the stock. ALEC has been the topic of several other research reports. Cowen reiterated a buy rating on shares of Alector in a research report on Monday, December 16th. […]
- 03/02/2020
|
Stocks To Watch: Time For Coronavirus Offense Or Defense?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 02/29/2020
|
Why Alector (ALEC) Could Be Positioned for a Surge
- Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- 02/28/2020
|
Why Alector (ALEC) Could Be Positioned for a Surge
- Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- 02/28/2020
|
Alector (NASDAQ:ALEC) Shares Down 10.2%
- Alector Inc (NASDAQ:ALEC)’s stock price was down 10.2% during trading on Monday . The stock traded as low as $26.53 and last traded at $27.35, approximately 988,012 shares traded hands during trading. An increase of 39% from the average daily volume of 713,242 shares. The stock had previously closed at $30.47. Several equities research analysts […]
- 02/25/2020
|
Alector to Present at the Cowen 40th Annual Health Care Conference
- SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon.
- 02/24/2020
|
Alector to Present at the Cowen 40th Annual Health Care Conference
- SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
- 02/24/2020
|
Contrasting Alector (NASDAQ:ALEC) & Coherus Biosciences (NASDAQ:CHRS)
- Alector (NASDAQ:ALEC) and Coherus Biosciences (NASDAQ:CHRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Profitability This table compares Alector and Coherus Biosciences’ net margins, return on equity and return on assets. […]
- 02/24/2020
|
Cannell Peter B & Co. Inc. Acquires 23,125 Shares of Alector Inc (NASDAQ:ALEC)
- Cannell Peter B & Co. Inc. grew its holdings in Alector Inc (NASDAQ:ALEC) by 24.8% in the 4th quarter, Holdings Channel reports. The fund owned 116,250 shares of the company’s stock after purchasing an additional 23,125 shares during the quarter. Cannell Peter B & Co. Inc.’s holdings in Alector were worth $2,003,000 as of its […]
- 02/23/2020
|
Stifel Nicolaus Begins Coverage on Alector (NASDAQ:ALEC)
- Stifel Nicolaus assumed coverage on shares of Alector (NASDAQ:ALEC) in a research report report published on Tuesday morning, BenzingaRatingsTable reports. The firm issued a buy rating on the stock. Several other brokerages have also recently weighed in on ALEC. Cowen reiterated a buy rating on shares of Alector in a report on Monday, December 16th. […]
- 02/21/2020
|
Oppenheimer & Co. Inc. Grows Position in Alector Inc (NASDAQ:ALEC)
- Oppenheimer & Co. Inc. raised its stake in Alector Inc (NASDAQ:ALEC) by 101.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 129,032 shares of the company’s stock after acquiring an additional 65,060 shares during the quarter. Oppenheimer & Co. Inc. owned […]
- 02/21/2020
|
Stifel likes Alector and Denali in premarket analyst action
- Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca
- 02/19/2020
|
IPO Update: Passage Bio Finalizes $126 Million IPO Plan
- Passage Bio has filed to raise $126 million in an IPO of its common stock. The firm is a pre-clinical biopharma working on monogenic treatments for central nerv
- 02/18/2020
|
Alector Inc (NASDAQ:ALEC) VP Calvin Yu Sells 63,541 Shares
- Alector Inc (NASDAQ:ALEC) VP Calvin Yu sold 63,541 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $30.04, for a total value of $1,908,771.64. Following the completion of the sale, the vice president now directly owns 188,835 shares in the company, valued at […]
- 02/08/2020
|
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- 02/07/2020
|
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
- 02/06/2020
|
Alector Inc (NASDAQ:ALEC) Insider Sells $224,000.00 in Stock
- Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $28.00, for a total transaction of $224,000.00. Following the completion of the transaction, the insider now owns 281,719 shares of the company’s stock, valued […]
- 02/06/2020
|
Alector (NASDAQ:ALEC) Trading 7.1% Higher Following Insider Buying Activity
- Alector Inc (NASDAQ:ALEC) shares traded up 7.1% during mid-day trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $31.00 and last traded at $30.18, 1,287,034 shares traded hands during mid-day trading. An increase of 96% from the average session volume of 655,488 shares. The stock had […]
- 02/06/2020
|
9 Stocks to Buy to Profit Off the Baby Boomer Generation
- While most investors may focus exclusively on the millennials, it’s the baby boomers that could be the most relevant for Wall Street.
- 02/05/2020
|
Alector's AL101 Fast Track'd for FTD; shares up 7%
- The FDA designates Alector's (ALEC +6.8%) AL101 for Fast Track review for the treatment of patients with progranulin gene mutations causing frontotemporal dementia (FTD).Phase 1-stage AL101 is
- 02/05/2020
|
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia
- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN). AL101, the company’s second product candidate designed to restore progranulin levels in the brain, is currently being evaluated in a Phase 1 trial in healthy volunteers.
- 02/05/2020
|
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- 02/05/2020
|
David Wehner Is The Independent Director of Alector, Inc. (NASDAQ:ALEC) And They Just Spent US$500k On Shares
- Investors who take an interest in Alector, Inc. (NASDAQ:ALEC) should definitely note that the Independent Director...
- 02/05/2020
|
Trade Alert: The Independent Director Of Alector, Inc. (NASDAQ:ALEC), David Wehner, Has Just Spent US$500k Buying Shares
- Investors who take an interest in Alector, Inc. (NASDAQ:ALEC) should definitely note that the Independent Director...
- 02/05/2020
|
Passage Bio Files Initial Plan For IPO
- Passage Bio has filed to raise $125 million in an IPO, although the final figure may differ. The firm is advancing a pipeline of genetic treatment candidates fo
- 02/04/2020
|
Alector Inc (NASDAQ:ALEC) Director David M. Wehner Purchases 20,000 Shares
- Alector Inc (NASDAQ:ALEC) Director David M. Wehner bought 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were bought at an average cost of $28.19 per share, for a total transaction of $563,800.00. Following the purchase, the director now directly owns 44,621 shares in the company, valued at approximately […]
- 02/04/2020
|
Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic
- A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania. Now the
- 02/04/2020
|
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its previously announced underwritten public offering of 9,602,500 shares of its common stock at the public offering price of $25.00 per share. Alector received total gross proceeds of approximately $240.0 million, before deducting the underwriting discounts and commissions and other offering expenses. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and Cowen acted as joint book-running managers for the offering.
- 02/03/2020
|
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- - Total gross proceeds from the offering to Alector are approximately $240 million
- 02/03/2020
|
Alector (NASDAQ:ALEC) Sees Unusually-High Trading Volume
- Alector Inc (NASDAQ:ALEC) saw unusually-strong trading volume on Friday . Approximately 26,062 shares traded hands during trading, a decline of 94% from the previous session’s volume of 440,545 shares.The stock last traded at $28.14 and had previously closed at $28.17. Several equities analysts have commented on ALEC shares. Cowen reaffirmed a “buy” rating on shares […]
- 02/02/2020
|
Zacks Investment Research Lowers Alector (NASDAQ:ALEC) to Hold
- Alector (NASDAQ:ALEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and […]
- 02/02/2020
|
Alector (NASDAQ:ALEC) Hits New 1-Year High at $28.00
- Alector Inc (NASDAQ:ALEC) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $28.00 and last traded at $26.75, with a volume of 53606 shares traded. The stock had previously closed at $25.94. A number of brokerages recently issued reports on ALEC. Zacks Investment Research cut Alector […]
- 02/01/2020
|
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- 01/31/2020
|
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering
- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters fully exercised their option to purchase an additional 1,252,500 shares of common stock at the offering price of $25.00 per share in connection with the company’s previously announced public offering of common stock. After giving effect to this exercise of the underwriters’ option, the total number of shares sold by Alector in the public offering will be 9,602,500 and total gross proceeds to Alector from the offering are expected to be approximately $240.0 million, before deducting underwriting discounts and commissions and other offering expenses.
- 01/31/2020
|
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering
- Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million
- 01/31/2020
|
IFR US ECM Calendar
- NEW YORK, Jan 30 (IFR) -
- 01/30/2020
|
Alector Announces Upsizing and Pricing of Public Offering
- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.00 per share pursuant to a registration statement on Form S-1 filed previously with the U.S. Securities and Exchange Commission (SEC). The offering was upsized to 8,350,000 shares of Alector’s common stock from the original offering size of 5,095,000 shares of common stock.
- 01/30/2020
|
Alector Announces Upsizing and Pricing of Public Offering
- Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million
- 01/30/2020
|
IFR US ECM Calendar
- NEW YORK, Jan 29 (IFR) -
- 01/30/2020
|
UPDATE 1-IFR US ECM Calendar
- (Adds Live Nation Entertainment CB.)
- 01/29/2020
|
CORRECTED-IFR US ECM Calendar
- (Corrects headline)
- 01/29/2020
|
Sabah Oney Sells 14,467 Shares of Alector Inc (NASDAQ:ALEC) Stock
- Alector Inc (NASDAQ:ALEC) insider Sabah Oney sold 14,467 shares of Alector stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $25.05, for a total transaction of $362,398.35. Following the completion of the sale, the insider now directly owns 596,118 shares in the company, valued at approximately $14,932,755.90. […]
- 01/29/2020
|
IFR US ECM Calendar
- NEW YORK, Jan 28 (IFR) -
- 01/29/2020
|
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients
- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003. AL003 is Alector’s second clinical-stage program targeting Alzheimer’s disease and is being developed in collaboration with its partner, AbbVie.
- 01/28/2020
|
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, ...
- 01/28/2020
|
15 Biotechnology Stocks Moving In Thursday's After-Market Session
-
Gainers
• Alector, Inc. (NASDAQ:ALEC) stock rose 10.8% to $25.79 during Thursday's after-market session. The most recent rating by BTIG, on November 21, is at Buy...
- 01/24/2020
|
What Company Will Eli Lilly Buy Next?
- Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
- 01/23/2020
|
13D Filings
- Activists file with the SEC—GCP Applied Technologies and nine other companies
- 01/18/2020
|
Anaemia, high haemoglobin levels can increase risk of developing dementia
- High levels, just like low, can also be a sign of a health problem.
- 08/05/2019
|
